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Tyrosine Sulfation of the Amino Terminus
of CCR5 Facilitates HIV-1 Entry
(Cocchi et al., 1995; Gong et al., 1998). In humans, HIV-1
isolates that use CCR5 predominate during the asymp-
tomatic stages of infection (Connor et al., 1997). As in-
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tyrosine sulfation (Rosenquist and Nicholas, 1993;
Bundgaard et al., 1997). Scanning mutagenesis experi-
ments have shown that these tyrosines and acidic aminoSummary
acids in the N terminus of CCR5 contribute to the ability
of CCR5-using HIV-1 and SIV to fuse with and enterChemokine receptors and related seven-transmem-
target cells (Dragic et al., 1998; Farzan et al., 1998; Rabutbrane-segment (7TMS) receptors serve as corecep-
et al., 1998; Ross et al., 1998). The ability of solubletors for entry of human and simian immunodeficiency
complexes of the HIV-1 gp120 exterior envelope glyco-viruses (HIV-1, HIV-2, and SIV) into target cells. Each
protein and CD4 to bind CCR5 is likewise dependentof these otherwise diverse coreceptors contains an
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roles in HIV-1 entry. The HIV-1 envelope glycoproteinthe binding of CCR5 to MIP-1a, MIP-1b, and HIV-1
gp120 binds sulfated proteoglycans on the cell surface
gp120/CD4 complexes and to the ability of HIV-1 to
(Roderiquez et al., 1995; Mondor et al., 1998). This asso-
enter cells expressing CCR5 and CD4. CXCR4, another
ciation has been demonstrated to occur at, or near, the
important HIV-1 coreceptor, is also sulfated. Tyrosine
third variable (V3) loop of gp120, which largely deter-
sulfation may contribute to the natural function of
mines viral tropism and, equivalently, coreceptor use
many 7TMS receptors and may be a modification com- (Hwang et al., 1991; Roderiquez et al., 1995; Choe et al.,
mon to primate immunodeficiency virus coreceptors. 1996). In addition, several multiply sulfated compounds
have been shown to inhibit HIV-1 infection in vitro by
binding to gp120, again in regions proximal to its V3Introduction
loop (Yang et al., 1996; Este et al., 1997; Zhang et al.,
1998). Finally, chemokines themselves bind heparan sul-Chemokine receptors belong to a larger family of G pro-
fate and related glycosaminoglycans, which are thoughttein±coupled seven-transmembrane-segment (7TMS)
to anchor the chemokine for recognition by the receptor-receptors, which have diverse and important roles in
bearing leukocyte (Tanaka et al., 1993; Webb et al., 1993;many biological processes (Premack and Schall, 1996).
Luster et al., 1995). The presence of heparan sulfate onThe chemokine receptor CCR5 serves as a coreceptor,
the surface of target cells has been shown to augment
together with CD4, for HIV and SIV and facilitates entry
the ability of CCR5's natural chemokine ligands to inhibit
of these viruses into their target cells (Alkhatib et al.,
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We show here that CCR5 is modified by O-linked gly-
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cosylation and by tyrosine sulfation of its N terminus.
MIP-1a, MIP-1b, RANTES, and MCP-2Ðinhibit replica-
An inhibitor of tyrosine sulfation does not affect CCR5
tion of HIV-1 isolates that use CCR5 as a coreceptor expression, but it substantially decreases the affinity
of MIP-1a, MIP-1b, and gp120/CD4 complexes for the
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We first examined whether CCR5 was modified by
N-linked glycosylation, as the third extracellular loop of
the protein contains a potential N-linked glycosylation
site. Consistent with other reports (Rucker et al., 1996),
neither the N-glycosidase endo F nor tunicamycin treat-
ment of Cf2Th-CD4/CCR5 cells resulted in a change
in CCR5 mobility on SDS-PAGE (data not shown). By
contrast, a shift in the mobility of CD4 was observed in
the same tunicamycin-treated Cf2Th-CD4/CCR5 cells
(data not shown).
Like most b-chemokine receptors, CCR5 also con-
tains several extracellular regions rich in serines and
threonines, which could be modified by O-linked glyco-
sylation. In the case of CCR5, two such regions areFigure 1. CCR5 Specifically Incorporates [35S]Sulfate
present in its N terminus and one each is present in its
Cf2Th cells (lanes 1, 3, 5, and 7) or Cf2Th-CD4/CCR5 cells (lanes 2,
second and third extracellular loops (Raport et al., 1996;4, 6, and 8) were labeled with [35S]cysteine and methionine (lanes
Samson et al., 1996). The anti-CCR5 antibody 5C7 was1±4) or [35S]sulfate (lanes 5±8). Cells were lysed, immunoprecipitated
used to precipitate lysates of Cf2-CCR5 cells radiola-with the anti-CCR5 antibody 5C7 (lanes 1, 2, 5, and 6) or anti-CD4
antibody OKT4a (lanes 3, 4, 7, and 8), and analyzed by SDS-PAGE. beled with [35S]cysteine and [35S]methionine or with
Lanes 1±4 represent a 12 hr film exposure, whereas lanes 5±8 derive [35S]sulfate. Immunoprecipitates were either treated with
from the same gel exposed for 48 hr. Numbers on the left indicate neuraminidase alone, a cocktail of O-glycosidases, or
the positions of molecular weight markers.
enzyme buffer only. As shown in Figure 2A, the mobility
in SDS-PAGE of CCR5 labeled with [35S]Cys/Met was
and are markedly less efficient in their ability to support increased by treatment with neuraminidase (lane 6) and
the entry of several macrophage-tropic and dual-tropic more so when treated with a mixture of O-glycosidases
viruses into target cells. We also show that full-length (lane 7). The CCR5 signal from immunoprecipitates of
CXCR4, another major HIV-1 coreceptor (Feng et al.,
cells labeled with [35S]sulfate displayed an identical pat-
1996), is sulfated. These data contribute to our under-
tern with no loss of signal intensity (lanes 1±3). Thus,
standing of the chemokine receptors' association with
enzymatic treatments of CCR5 that remove O-linkedtheir natural ligands and with HIV-1 and SIV envelope
glycosylation do not remove the sulfated moieties onglycoproteins.
CCR5. We conclude that CCR5 contains O-linked carbo-
hydrates that include sialic acid, but these sugar moi-Results
eties do not appear to account for the majority of CCR5
sulfation.CCR5 Is Posttranslationally Modified by Sulfate
Both chemokines and HIV-1 envelope glycoproteins
have been demonstrated to bind sulfate moieties (Ta- CCR5 Tyrosines Are Modified by Sulfate
naka et al., 1993; Webb et al., 1993; Roderiquez et al., To demonstrate that CCR5 was sulfated at its tyrosines,
1995; Yang et al., 1996; Este et al., 1997; Mondor et al., we extracted the [35S]sulfate-labeled CCR5 band shown
1998; Zhang et al., 1998). Additionally, a tyrosine-rich in Figure 1 (lane 6), hydrolyzed the peptide bonds with
region in the amino terminus of CCR5, which has been Ba(OH)2, and performed amino acid analysis (Huttner,
shown to be important for HIV-1 and SIV entry (Dragic 1984). Hydrolyzed [35S]sulfate-labeled CCR5 was mixed
et al., 1998; Farzan et al., 1998; Rabut et al., 1998; Ross with unlabeled tyrosine sulfate to facilitate ninhydrin
et al., 1998), shares similarity with tyrosine-sulfated re- staining, and electrophoresis was performed on this
gions of other proteins (Rosenquist and Nicholas, 1993; mixture spotted on a thin layer chromatography (TLC)
Bundgaard et al., 1997). We thus examined whether plate (Figure 2B, lanes 2 and 4). Unlabeled tyrosine and
CCR5 was sulfated. serine sulfate were run as standards (lanes 1 and 3). As
Cf2Th canine thymocytes that stably express CCR5 shown in the autoradiograph of the TLC plate (lanes 3
and CD4 (Cf2-CD4/CCR5 cells) were incubated with and 4), most of the [35S]sulfate signal comigrated with
[35S]cysteine and [35S]methionine or sodium [35S]sulfate a tyrosine sulfate standard (lanes 2 and 4) faster than
for 24 hr. Cell lysates were immunoprecipitated with phenol red and slower than serine sulfate (lane 1). Taken
the anti-CCR5 antibody 5C7 or the anti-CD4 antibody together, these data indicate that the incorporation of
OKT4a and analyzed by SDS-PAGE. As shown in Figure [35S]sulfate by CCR5 is largely or solely a result of the
1, although CCR5 and CD4 (lanes 2 and 4, respectively) tyrosine sulfation.
were both clearly detectable in immunoprecipitates of
cysteine- and methionine-labeled cells, only CCR5 was
Sulfation Inhibitor Chlorate Lowers Chemokinedetected in immunoprecipitates of cells labeled with
and gp120/CD4 Binding Affinity for CCR5[35S]sulfate (lane 6). These results show that [35S]sulfate
but Not CCR5 Expressionis specifically incorporated into native CCR5.
To assess the role of tyrosine sulfation in CCR5's associ-
ation with its known ligands, we treated Cf2-CCR5-CD4CCR5 Is Modified by O- but Not
cells with 10 mM sodium chlorate or 10 mM magnesiumN-Linked Glycosylation
sulfate for 16 hr in sulfate-free media. Chlorate is a rela-Sulfate can be incorporated into proteins at sites of N- or
O-linked glycosylation or on tyrosines (Huttner, 1988). tively nontoxic inhibitor of sulfation (Mintz et al., 1994;
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Figure 3. FACS Analysis of Chlorate-Treated Cells with the Anti-
CCR5 Antibodies 5C7 and 2D7
Cf2Th-CCR5 or Cf2Th cells were incubated in sulfate-free media in
the presence of 10 mM sodium chlorate or 10 mM magnesium sulfate
for 16 hr. Cells were washed twice and stained with the second
extracellular loop anti-CCR5 antibody 2D7 (A) or the N-terminal anti-
CCR5 antibody 5C7 (B). The FACS profiles of chlorate-treatedFigure 2. CCR5 Is Modified by O-Glycosylation and Tyrosine Sul-
Cf2Th-CCR5 cells are indicated in filled gray, and that of sulfate-fation
treated Cf2Th-CCR5 cells are indicated by a thick black line. The
(A) O-glycosidases alter CCR5's mobility on SDS-PAGE. Cf2 cells FACS profile of sulfate-treated Cf2Th control cells is indicated with
(lanes 4 and 8) or Cf2Th-CD4/CCR5 cells (lanes 1±3 and 5±7) were a thinner black line. Mean fluorescence measured by 2D7 was 185.2,
labeled with [35S]sulfate (lanes 1±4) or [35S]cysteine and methionine 182.5, and 9.4 for sulfate-treated Cf2Th-CCR5, chlorate-treated
(lanes 5±8), lysed, and immunoprecipitated with the anti-CCR5 anti- Cf2Th-CCR5, and control Cf2Th cells, respectively. Mean fluores-
body 5C7. Immunoprecipitates were treated with enzyme buffer cence measured by 5C7 was 143.6, 56.1, and 8.6 for sulfate-treated
alone (lanes 1, 4, 5, and 8), neuraminidase (lanes 2 and 6), or a Cf2Th-CCR5, chlorate-treated Cf2Th-CCR5, and control Cf2Th
cocktail of four O-glycosidases (lanes 3 and 7). Lanes 1±4 represent cells, respectively. The figure shows a representative experiment
a 36 hr film exposure, whereas lanes 5±8 derive from the same gel of five independent FACS analyses performed in parallel with the
exposed for 12 hr. Numbers on the left indicate the positions of experiments of Figures 4, in which 2D7 staining of chlorate-treated
molecular weight markers. Cf2Th-CCR5 cells and Cf2Th control cells was 103% 6 8.1% and
(B) Thin layer chromatography of tyrosine sulfate derived from full- 8.9% 6 5.4%, respectively, of Cf2Th-CCR5 cells treated with sulfate.
length CCR5. [35S]sulfate-labeled CCR5 was excised from the poly- 5C7 staining of chlorate-treated Cf2Th-CCR5 cells and Cf2Th con-
acrylamide gel exposed for Figure 1, lane 6, and digested at 1108C trol cells was 37.3% 6 11.1% and 11.6% 6 5.7%, respectively, of
for 24 hr in Ba(OH)2 in the presence of unlabeled tyrosine sulfate. Cf2Th-CCR5 cells treated with sulfate.
Digests were pH neutralized with sulfuric acid in phenol red, dried
and resuspended in TLC electrophoresis buffer, spotted on a TLC
plate, and run for 20 min at 1000 V (lanes 2 and 4) next to unlabeled
antibody could not distinguish between chlorate- andtyrosine and serine sulfate (lanes 1 and 3). The TLC plate was stained
with ninhydrin to visualize amino acids (lanes 1 and 2), and an sulfate-treated cells (Figure 3A). We conclude that chlo-
autoradiograph was made using the same TLC plate (lanes 3 and 4). rate does not interfere with the expression of CCR5 or
with its conformation insofar as the latter can be as-
sessed by the integrity of the 2D7 epitope. However,
chlorate treatment does affect 5C7 binding, indicatingPouyani and Seed, 1995). We first analyzed chlorate-
and sulfate-treated cells by FACS with two CCR5 anti- that in chlorate-treated cells, the CCR5 N terminus is
specifically altered. 5C7 also failed to recognize a CCR5bodies, 5C7 and 2D7, raised against human CCR5 ex-
pressed in murine cells (Wu et al., 1997). 5C7 recognizes variant in which the N-terminal tyrosines had been al-
tered to phenylalanine (data not shown), supporting thea linear epitope at the N terminus of CCR5, whereas
2D7 recognizes a conformation-dependent epitope that notion that the lower recognition of CCR5 by 5C7 follow-
ing chlorate treatment is due to the loss of sulfate, rathermaps largely to the second extracellular loop of CCR5
(Wu et al., 1997). FACS analysis of the Cf2-CCR5-CD4 than a nonspecific effect of chlorate. The broad distribu-
tion of the 5C7 FACS profile of the chlorate-treated cellscells showed that the N-terminal CCR5 antibody 5C7 is
sensitive to chlorate treatment (Figure 3B), whereas the may indicate that some sulfated CCR5 is still present
on these cells.FACS profiles of the same cells treated with the 2D7
Cell
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The abilities of the CCR5 ligands MIP-1a and MIP-1b
to bind to these same cells were analyzed. Cf2Th-CCR5
cells treated with chlorate (circles) bound 125I-MIP-1a
and 125I-MIP-1b less efficiently than sulfate-treated cells
(squares) (Figures 4A and 4B, respectively). FACS analy-
sis with the 2D7 antibody run in parallel with these exper-
iments showed no decrease in CCR5 expression in chlo-
rate-treated cells relative to sulfate-treated cells (Figure
4 legend). CCR5-negative Cf2Th cells (triangle) and
Cf2Th-CCR5 cells treated with 4 mg of the anti-CCR5
antibody 2D7 (diamond) showed little ability to bind 125I
MIP-1a or 125I MIP-1b, demonstrating that the observed
interactions were specific for CCR5. Background values
of chemokine binding to both CCR5-negative cells and
2D7-treated CCR5-Cf2Th cells were unchanged in the
presence or absence of chlorate (data not shown).
Previous studies showed that the gp120 envelope gly-
coprotein of CCR5-using HIV-1 isolates, when com-
plexed with soluble CD4 (sCD4), bound CCR5-express-
ing cells with high affinity (Trkola et al., 1996; Wu et al.,
1996). As shown in Figure 4C, complexes of sCD4 and
soluble 125I-labeled gp120 from the CCR5-using HIV-1
isolate YU2 bound chlorate-treated Cf2Th-CCR5 cells
(circles) less efficiently than those treated with sulfate
(squares). Again, FACS analysis run in parallel demon-
strated that the anti-CCR5 antibody 2D7 stained chlo-
rate-treated Cf2Th-CCR5 cells as efficiently as cells
treated with sulfate (Figure 4C legend). In the presence
of 4 mg of 2D7, 125I-labeled gp120/CD4 complexes bound
chlorate-treated Cf2Th cells (diamond) with the same
low efficiency as Cf2Th control cells lacking CCR5 (trian-
gles), or cells treated with 100 nM cold gp120 competitor
(rightmost square and circle). These results demonstrate
that chlorate interferes with the ability of gp120/CD4
complexes to bind CCR5 specifically. We conclude that
chlorate treatment of Cf2Th-CCR5 cells does not inter-
fere with the expression of CCR5 or its recognition by
the conformation-dependent 2D7 antibody, but it does
interfere with the ability of HIV-1 gp120 and CCR5's
Figure 4. Association of Chemokines and gp120/CD4 Complexes
natural ligands to bind CCR5, consistent with an influ-with Cf2Th-CCR5 Cells Is Inhibited by Chlorate
ence of sulfated tyrosines on the efficiency of these(A) Cf2Th-CCR5 cells (0.5 3 106) were treated with sulfate or chlorate
associations.as described in Figure 6, washed twice, and incubated for 1 hr at
258C with 0.1 nM 125I-labeled MIP-1a and increasing amounts of cold
MIP-1a competitor. Sulfate-treated cells are indicated with squares;
chlorate-treated cells, with circles; sulfate-treated cells in the pres- Sulfation of Specific N-Terminal Tyrosines
ence of 4 mg 2D7 antibody are indicated with a diamond, and Cf2Th We next sought to determine which of the four N-termi-
control cells are indicated with a triangle. FACS measurements per- nal tyrosines of CCR5 are sulfated. To enhance expres-
formed on the same cells in parallel with the anti-CCR5 antibodies sion of CCR5 variants, a codon-optimized CCR5 con-2D7 and 5C7 gave mean fluorescence values for chlorate-treated
struct tagged at its C terminus with nine amino acids ofcells that were 106.5% 6 8.4% and 38.4% 6 0.4%, respectively, of
rhodopsin (T. M. and J. S., unpublished data) was usedthose for sulfate-treated cells.
(B) The same experiment as described in (A), except that 0.1 nM for these studies. This construct, and variants thereof,
125I-labeled MIP-1b is incubated with cold MIP-1b competitor. FACS could be efficiently precipitated with the anti-rhodopsin
measurements performed on the same cells in parallel with the anti- antibody 1D4 (Figure 5).
CCR5 antibodies 2D7 and 5C7 gave mean fluorescence values for Initially, a series of codon-optimized CCR5 variantschlorate treated-cells that were 103% 6 5.1% and 31.1% 6 7.0%,
in which some or all of its N-terminal tyrosines had beenrespectively, of those for sulfate-treated cells.
altered to phenylalanine were assayed for their ability(C) Cf2Th-CCR5 cells (0.5 3 106) were treated with sulfate or chlorate
as described above, washed and incubated for 1 hr at 258C with 0.1 to incorporate sulfate. HeLa cells were transfected with
nM 125I-YU2 gp120 and unlabeled 100 nM soluble CD4 with increas- codon-optimized wild-type CCR5, a construct in which
ing amounts of unlabeled YU2 gp120 competitor. FACS measure- all four of the N-terminal tyrosines had been altered to
ments performed on the same cells in parallel with the anti-CCR5 phenylalanine (FFFF), or constructs in which three outantibodies 2D7 and 5C7 gave mean fluorescence values for chlorate-
of four tyrosines had been altered to phenylalanine (con-treated cells that were 97.5% 6 5.5% and 42.6% 6 5.3%, respec-
structs YFFF, FYFF, FFYF, and FFFY, with each lettertively, of those for sulfate-treated cells. Figures represents an aver-
age and range of two (A and B) or three (C) independent experiments. representing the amino acid residue at position 3, 10,
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and FFFY after extended exposure (data not shown).
The efficiency of the sulfate incorporation into YFFF was
significantly lower than wild-type CCR5 when compared
with their cysteine- and methionine-labeled counter-
parts. Additionally, a construct expressing the last three
tyrosines in the N terminus of CCR5 (FYYY) is sulfated
far more efficiently than the sum of FYFF, FFYF, and
FFFY (Figures 5A and 5C). These data imply that tyrosine
3 and at least one additional tyrosine in the CCR5 N
terminus are sulfated, but that the presence of phenylal-
anines or the absence of proximal tyrosines retards the
sulfation of constructs FYFF, FFYF, and FFFY.
To examine the presence of sulfation in a different
context, an additional panel of CCR5 mutants was made
and tested for their ability to incorporate sulfate. A
CCR5-derived construct (DDDD) in which each of the
tyrosines was mutated to aspartic acid, and those in
which three of four tyrosines were altered to aspartic
acid (YDDD, DYDD, DDYD, and DDDY), were assayed.
As shown in Figure 5B, the DDDD construct could not
incorporate any detectable sulfate. Each of the con-
structs containing a single tyrosine could efficiently in-
corporate sulfate. The efficient sulfation of these con-
structs contrasts with the low levels of sulfation of the
FYFF, FFYF, and FFFY variants. Together, these results
suggest the possibility that the negative charges of the
sulfate group itself contribute to the subsequent sul-
fation of nearby tyrosines.
Sulfated Tyrosines Contribute to the Efficiency
of HIV-1 Entry
To determine a role for the CCR5 tyrosine sulfates in
HIV-1 entry, we compared the ability to support HIV-1
infection of CCR5 variants shown to be sulfated (Figure
5) with analogous variants in which the sulfated tyrosine
was altered to phenylalanine. Figure 6A shows that vi-
Figure 5. Sulfation of Specific CCR5 Tyrosines Is Dependent
ruses pseudotyped with the envelope glycoprotein ofN-Terminal Residues
the YU2 HIV-1 isolate were sensitive to alteration of all
(A) Plasmids encoding codon-optimized CCR5 constructs con-
of the N-terminal tyrosines to phenylalanine (constructtaining a C-terminal tag in which some or all of the N-terminal tyro-
FFFF, circles in Figure 6A), at comparable expressionsines have been modified to phenylalanine were transiently trans-
fected into HeLa cells, labeled with [35S]cysteine and methionine or levels of mutant and wild-type receptors. Both of the
[35S]sulfate, as indicated, and precipitated with the C-terminal tag viruses pseudotyped with the envelope glycoproteins
antibody 1D4. Cells were transfected with vector alone, wild-type of the primary HIV-1 isolates ADA, and 89.6 exhibited
codon-optimized CCR5, a codon-optimized CCR5 construct in greater sensitivity to the loss of the hydroxyl and/or
which all four tyrosines had been altered to phenylalanine (construct
sulfate moieties at the N terminus, with 89.6 entry valuesFFFF), or constructs in which three of four tyrosines had been altered
into cells expressing the FFFF construct at levels equiva-to phenylalanine (constructs YFFF, FYFF, FFYF, and FFFY, which
have intact tyrosines at positions 3, 10, 14 and 15, respectively). lent to that of CCR5-negative Cf2Th cells (circles in Fig-
(B) Same experiment as in (A) except that every combination of ures 6B and 6C). Entry of all three viruses was at or near
three or all four tyrosines has been altered to aspartic acids. background when each of the N-terminal tyrosines was
(C) Same experiment as in (A) except that wild-type CCR5 (construct altered to aspartic acid (construct DDDD, triangles in
YYYY) and constructs YFFF and FYYY are compared.
Figures 6A±6C), indicating some role in HIV-1 entry for
the phenyl group of the tyrosines as well.
We then compared the efficiency of virus entry associ-14, and 15, respectively). Cells labeled with either
[35S]cysteine and methionine or [35S]sulfate were lysed, ated with the DDDD construct to that of constructs in
which one of the four aspartic acids present in DDDDand the CCR5 variants were immunoprecipitated with
the antibody 1D4. Figure 5A shows that wild-type CCR5 was restored to a tyrosine. Each of these restored tyro-
sines is modified by sulfate (Figure 5B). The 89.6 viruscould incorporate sulfate and that construct FFFF failed
to incorporate any detectable sulfate, excluding the exhibited background entry levels in cells expressing
the FFFF, DDDD, YDDD, DYDD, DDYD, and DDDY con-presence of sulfate on regions other than CCR5's N
terminus. Of the remaining constructs, only YFFF could structs (Figure 6C and data not shown). However, cells
expressing the DYDD, DDYD, and DDDY variants showedefficiently incorporate sulfate, although very faint bands
were visible in lanes of immunoprecipitated FYFF, FFYF, a significant increase in their ability to support infection
Cell
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by ADA and YU2 pseudotyped viruses, as compared
with cells expressing the DDDD protein. The entry of
the ADA and YU2 viruses into cells expressing the YDDD
construct was close to, but still detectably greater than,
entry into cells expressing the DDDD protein (Figures
6D and 6E). These data demonstrate that the presence
of sulfated tyrosines at positions 10, 14, and 15, and to
a lesser extent at position 3, contributes substantially
to CCR5's ability to support infection by two primary
HIV-1 viruses.
To distinguish the role of the sulfate group from that
of the phenyl ring of the sulfated tyrosine, we compared
directly the coreceptor function of the DYDD, DDYD, and
DDDY constructs with their unsulfated analogs (DFDD,
DDFD, and DDDF, respectively). As summarized in Fig-
ures 6D and 6E, the efficiency with which viruses pseu-
dotyped with the ADA and YU2 envelope glycoproteins
infected cells expressing each construct lacking a sul-
fate group was substantially less than that of cells ex-
pressing CCR5 variants in which the sulfate was present.
Specifically, the DFDD variant supported entry of YU2
and ADA viruses at 33% and 30%, respectively, of the
infection levels supported by the DYDD construct. Simi-
larly, the DDFD protein supported YU2 and ADA virus
entry at 15% and 10%, respectively, of that observed
for the DDYD variant, and the DDDF protein supported
YU2 and ADA virus entry at 34% and 10%, respectively,
of that observed for the DDDY construct. We conclude
that the presence of a sulfate moiety on tyrosines 10,
14, and 15 of CCR5 substantially enhances the entry of
at least two primary HIV-1 viruses.
Sulfation of CXCR4
Because the N termini of many chemokine receptors
and other 7TMS receptors that serve as primate immu-
nodeficiency virus coreceptors contain regions that re-
semble those of molecules known to be tyrosine sulfated
(Rosenquist and Nicholas, 1993; Bundgaard et al., 1997),
we examined whether these N termini could be sulfated.
Chimeric molecules consisting of a signal sequence, the
N termini of several 7TMS receptors, and the hinge and
final two constant domains of the human immunoglobu-
lin IgG1 heavy chain were expressed in HeLa cells, which
were radiolabeled with [35S]sulfate. Cell supernatants
were immunoprecipitated with protein A-Sepharose and
analyzed by SDS-PAGE. The N termini of each of the
activity, is plotted against the expression level for wild-type CCR5
(squares), for a construct in which each of the N-terminal tyrosines
is changed to phenylalanine (construct FFFF, circles), and for a
Figure 6. Sulfate on Tyrosines Contributes to the Efficiency of HIV-1 construct in which the same tyrosines are changed to aspartic acid
Entry (construct DDDD, triangles). The entry of viruses pseudotyped with
Varying amounts of plasmid DNA encoding wild-type codon-opti- the YU2 envelope glycoproteins is shown in (A), with the ADA enve-
mized CCR5 or codon-optimized CCR5 variants expressing alter- lope glycoproteins in (B), and with the 89.6 envelope glycoproteins in
ations in their N-terminal tyrosines were cotransfected with a plas- (C). The entry of viruses pseudotyped with the YU2 or ADA envelope
mid expressing CD4 into Cf2Th cells. Transfected cells were glycoproteins is shown in (D) and (E), respectively, using a larger
incubated for 1 hr with HIV-1 virus containing a CAT reporter gene panel of CCR5 variants. Figures (D) and (E) represent an average
and pseudotyped with envelope glycoproteins of the ADA, YU2, or and range of two or three experiments similar to that in (A)±(C),
89.6 primary HIV-1 isolates. In parallel, an aliquot of the same cells representing a total of at least six data points for each CCR5 con-
was analyzed for variant-CCR5 receptor surface expression by struct assayed. Entry is quantified as the percent entry on equiva-
FACS using the 2D7 antibody directed against the second extracel- lently expressed wild-type CCR5, a value determined from a stan-
lular loop of CCR5. A representative example of three experiments dard curve of virus entry versus surface expression of wild-type
with similar outcomes is shown. HIV-1 entry, as measured by CAT CCR5.
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Figure 7. CXCR4 Can Incorporate [35S]Sulfate
(A) The amino acid sequences of the N termini
of the receptors that when fused to the Fc
domains of IgG1 incorporate [35S]sulfate. Ty-
rosines and proximal acidic amino acids are
shown in bold. All receptors listed except
C5aR and CXCR3 have been reported to
function as HIV-1 and/or SIV coreceptors.
(B) 293T cells and 293T cells stably trans-
fected with CXCR4 containing a C-terminal
rhodopsin tag, as indicated, were labeled
with [35S]sulfate, immunoprecipitated with the
anti-rhodopsin antibody 1D4, and analyzed
by SDS-PAGE.
receptors shown in Figure 7A could efficiently incorpo- A number of diverse 7TMS receptors have been
shown to serve as HIV-1 or SIV coreceptors (Doms andrate [35S]sulfate in these fusion constructs (data not
shown). Neither the construct containing the IgG1- Peiper, 1997; Choe et al., 1998b; Littman, 1998). Despite
the fact that each of these receptors belongs to the Gderived domains alone nor one containing the second
extracellular loop of CCR5 could incorporate sulfate, protein±coupled family of 7TMS receptors and that
many of them are chemokine receptors, there is veryalthough both were efficiently expressed (data not
shown). These data raise the possibility that many 7TMS little obvious similarity among these receptors in their
external domains. One commonality is the presence ofreceptors, and in particular most or all of those receptors
reported to serve as HIV-1 or SIV coreceptors, contain an N-terminal region rich in tyrosines and acidic amino
acids. This motif has been useful in the identification ofN termini that can be modified by sulfation.
To further substantiate the hypothesis that sulfation new receptors for HIV-1 and SIV (Farzan et al., 1997a;
Choe et al., 1998a). The N termini of most of these recep-is a common modification of chemokine receptors and
of HIV-1 coreceptors, we investigated the sulfation of tors can be sulfated when expressed in a secreted fusion
construct, and full-length CXCR4 can also incorporateone additional HIV-1 coreceptor, the chemokine recep-
tor CXCR4. 293T cells or 293T cells expressing CXCR4 sulfate. These observations suggest that HIV and per-
haps SIV envelope glycoproteins conserve their abilitycontaining a C-terminal tag recognized by the antibody
1D4 were labeled with [35S]sulfate, lysed, and protein to interact with tyrosine sulfate, implying that the region
of gp120 which interacts with sulfated regions of thewas precipitated with 1D4 and protein A-Sepharose
beads. As shown in Figure 7B, a sulfated protein of coreceptor is itself conserved. A strongly positive region
of gp120, conserved among HIV-1 viruses of differenta size appropriate for CXCR4 was observed in cells
expressing CXCR4, but not in the parental 293T cells. clades and tropisms, has been shown to be important
for the association of gp120 with CCR5 (Kwong et al.,These data indicate that native CXCR4 is efficiently sul-
fated. 1998; Rizzuto et al., 1998; Wyatt et al., 1998). Addition-
ally, a conserved arginine in the third variable loop of
gp120 has been shown to be important for entry intoDiscussion
CXCR4- and CCR5-expressing cells (Wang et al., 1998).
Some of these positively charged residues may directlyThe N terminus of CCR5 contains four tyrosines at posi-
tions 3, 10, 14, and 15 (Raport et al., 1996; Samson interact with the large and highly polar sulfate group on
the primate immunodeficiency coreceptors.et al., 1996). Alteration of any one of these tyrosines
interferes with the ability of CCR5-using HIV-1 viruses While it is probable that tyrosine sulfates in the N
terminus of 7TMS molecules contribute to HIV corecep-to enter cells expressing mutant receptors (Farzan et
al., 1998; Rabut et al., 1998; Ross et al., 1998). We have tor function, it is unlikely that they are sufficient. 7TMS
molecules that have not been shown to function as HIV-1shown here that two or more of the tyrosines in this
region are sulfated and that chlorate, an inhibitor of coreceptors, like CXCR3 and the C5a receptor, nonethe-
less have N termini that may be tyrosine sulfated, andthis sulfation, did not affect CCR5 surface expression
but interfered with the ability of gp120/CD4 complexes not every coreceptor supports the entry of every HIV-1
variant. Also, other regions of CCR5 have been shownto bind CCR5. Moreover, we have shown that CCR5-
derived variants in which sulfate was documented to be to be important in HIV-1 entry (Doms and Peiper, 1997),
notably the second extracellular loop. Although thepresent on a single N-terminal tyrosine supported more
efficient entry of HIV-1 than analogous constructs lack- CCR5 second extracellular loop contains three tyrosine
residues, our data suggest that these are not sulfated.ing only the sulfate moiety. It is therefore likely that at
least one sulfated tyrosine in the N terminus of CCR5 Exactly why HIV-1 and SIV appear to adapt only to core-
ceptors that contain one or more sulfated tyrosines re-contributes to the formation of a surface important for
the association of CCR5 with the gp120 envelope glyco- mains to be explored further.
Glycosylation of CCR5 on serines and/or threoninesprotein.
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1430, respectively). Stable Cf2Th-CCR5 cell lines were made bymay also play some role in modulating the efficiency
transfection of Cf2Th cells with a pcDNA3 plasmid Invitrogen encod-with which HIV-1 enters specific target cells. It has been
ing CCR5 and selection with 0.8 mg/ml Neomycin. Stable Cf2Th-shown that proteins expressed in resting T cells, acti-
CD4/CCR5 cell lines were made by transfection of Cf2Th cells with
vated T cells, and macrophages have different O-linked the same pcDNA3 plasmid encoding CCR5 and a pCEP4 plasmid
glycosylation patterns (Carlsson et al., 1986; Fukuda encoding CD4 and selected with 0.8 mg/ml Neomycin and 0.1 mg/ml
Hygromycin. Stable CXCR4±293T cells were made by transfection ofet al., 1986). A closer examination of the differential
a pcDNA3 plasmid encoding CXCR4, and selection with 0.8 mg/mlregulation of O-linked glycosylation and tyrosine sul-
Neomycin. Anti-CCR5 antibodies 2D7 and 5C7 were a generous giftfation in different cell types, in different individuals, and
of LeukoSite, Inc. (Wu et al., 1997). Anti-rhodopsin antibody 1D4in different species may contribute to an understanding
was a generous gift of the National Cell Culture Center.
of variability in viral tropism and disease progression.
Inhibition of sulfation also interfered with the ability Plasmid Constructions
of MIP-1a and MIP-1b to bind cells expressing CCR5. Plasmids expressing CCR5 or CD4 were previously described (Choe
et al., 1996). Constructs expressing fusion proteins containing frag-Tyrosine sulfation of CCR5 thus appears to contribute
ments of CCR5 or other 7TMS receptors and the Fc domains ofto the binding of its natural ligands to this receptor. This
human IgGI were made by cloning the appropriate PCR fragmentsresult is consistent with a two-step model of chemokine
into a pCDM8 plasmid, generously provided by Dr. Brian Seed (Pou-
binding, in which the initial association is mediated by yani and Seed, 1995). DNA encoding a codon-optimized CCR5,
the N terminus of the receptor, whereas greater specific- which contains nine C-terminal residues derived from the C terminus
ity of the interaction is mediated by the remaining extra- of bovine rhodopsin, was generated by PCR and ligated into the
vector pcDNA3.1 (T. M. and J. S., unpublished data).cellular domains (Gerard and Gerard, 1994; Monteclaro
and Charo, 1996). Such a model may explain the disrup-
Labeling and Immunoprecipitation of CCR5, CXCR4, and CD4tion of MIP-1a binding by alteration of CCR5 N-terminal
Cf2Th or Cf2Th-CD4/CCR5 cells (5 3 106) were washed three timestyrosine residues (Farzan et al., 1998), whereas substitu-
in PBS and incubated for 24 hr at 378C in DMEM without cysteine
tion of the N terminus of CCR5 with that of CCR2, which and methionine with 200 mCi each [35S]cysteine and [35S]methionine,
is likely also sulfated, results in a receptor that retains or in sulfate-free media (ICN) with 500 mCi of [35S]sulfate (Dupont
a high affinity for MIP-1a (Farzan et al., 1997b; Samson NEN). Cells were lysed in 0.5% NP40-PBS and immunoprecipitated
with the anti-CCR5 antibody 5C7 or the anti-CD4 antibody OKT4aet al., 1997).
and protein A-Sepharose beads. Full-length codon-optimized CCR5Chemokines, including MIP-1a and MIP-1b, have
variants containing a C-terminal rhodopsin tag were similarly pre-been shown to bind to sulfated glycosaminoglycans
cipitated from transiently transfected HeLa cell lysates with the anti-
(GAGs) on cells and in the extracellular matrix, and ex- rhodopsin antibody 1D4. Full-length CXCR4 with the C-terminal
pression of GAGs on the surface of cells expressing rhodopsin tag was similarly immunoprecipitated from stably trans-
chemokine receptors enhances the activity of the che- fected 293T cells by the 1D4 antibody.
mokine, perhaps by tethering the chemokine for interac-
Detection of N- or O-Glycosylation on CCR5 and CD4tion with multiple receptors (Tanaka et al., 1993; Webb
CCR5 or CD4 was immunoprecipitated as above. Protein-A beadset al., 1993; Luster et al., 1995). It is possible that sulfated
and precipitates were incubated at 378C for 2 hr in a total volumeN termini serve an analogous function in contexts where
of 30 ml with neuraminidase buffer alone (50 mM sodium acetate
GAGs are not present or that they compete with GAGs [pH 5], 150 mM NaCl, 9 mM CaCl2), with endoglycosidase F and
for association with the chemokines to facilitate chemo- endo F buffer (50 mM potassium phosphate [pH 6.8], 25 mM EDTA,
kine internalization. Finally, it is possible that chemo- 0.5 NP40, 0.1% SDS), with 50 mU neuraminidase in neuraminidase
buffer, or with a cocktail of glycosidases containing 50 mU neur-kines, and perhaps HIV-1, make use of the fact that their
aminidase, 3 mU O-glycosidase, 25 mU b-galactosidase, and 100receptors are unsulfated in the endoplasmic reticulum
mU N-aceytl-b-D-glucosaminidase in O-glycosidase buffer (PBS,and Golgi apparatus, reducing the likelihood of ligand
1% Triton 3100, 0.5% SDS). All enzymes were obtained from Boeh-binding in these compartments in cells that express both
ringer Mannheim. Digested samples were analyzed by SDS-PAGE.
receptor and ligand.
Our results suggest that the N termini of many 7TMS Alkaline Hydrolysis and Amino Acid Analysis of Tyrosine
receptors, including many chemokine receptors and the Sulfate from CCR5
A [35S]sulfate-labeled band corresponding to CCR5 was excisedC5a receptor may be tyrosine sulfated. This sulfation
from a dried polyacrylamide gel and digested in 1 N Ba(OH)2 in themay contribute to the association of these negatively
presence of unlabeled tyrosine sulfate (Bachem) at 1108C for 24 hrcharged receptor N termini with their positively charged
and then neutralized with sulfuric acid using phenol red as an indica-ligands. A number of other 7TMS receptors including tor, as described (Huttner, 1984). The sample was dried and resus-
the Duffy antigen, CCR1, CCR4, CCR6, CXCR1, C3XCR1/ pended in electrophoresis buffer (5% acetic acid, 0.5% pyridine)
V28, the cytomegalovirus receptor US28, and the FMLP- and spotted on a cellulose-TLC plate (Macherey-Nagel) adjacent to
2 ng unlabeled tyrosine sulfate and 2 ng unlabeled serine sulfatelike receptor 1 also contain N-terminal motifs that sug-
(Bachem). Electrophoresis was performed at 1000 V for 20 min ingest the possible presence of sulfated tyrosines. Al-
electrophoresis buffer. The TLC plate was dried and placed on filmthough a more careful examination of the function of
for autoradiography, following visualization of unradiolabeled sul-tyrosine sulfation in each of these systems is required,
fated amino acids with 1% ninhydrin.
this posttranslational modification may play a wider role
in receptor-mediated biological processes than pre- Binding of HIV-1 gp120 Envelope Glycoprotein and Chemokines
viously appreciated. to Cf2Th-CCR5 Cells
Cf2Th-CCR5 cells were washed three times in PBS and incubated
16 hr in sulfate-free media (ICN) in which either magnesium sulfateExperimental Procedures
or sodium chlorate was added to a final concentration of 10 mM.
Cells were detached with PBS containing 5 mM EDTA. EDTA wasCells and Antibodies
chelated with the same volume of PBS containing 5 mM magnesiumHEK293T, HeLa, and Cf2Th cells were obtained from American Type
Culture Collection (ATCC CRL 11554, ATCC CCL 2, and ATCC CRL chloride, cells were washed 2 times in PBS, and resuspended in
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binding buffer (50 mM HEPES [pH 7.5], 1 mM CaCl2, 5 mM MgCl2, apj supports the entry of primary T-cell-line-tropic and dualtropic
human immunodeficiency virus type 1. J. Virol. 72, 6113±6118.0.5% BSA, 0.02% sodium azide) at 107 cells per milliliter. Fifty milli-
liters (0.5 3 106 cells) was then incubated for 1 hr at 258C with 50 Choe, H., Martin, K.A., Farzan, M., Sodroski, J., Gerard, N.P., and
ml binding buffer containing 0.1 nM 125I-labeled MIP-1a or MIP-1b Gerard, C. (1998b). Structural interactions between chemokine re-
(Dupont NEN) or 125I-labeled HIV-1 YU2 envelope glycoprotein gp120 ceptors, gp120 Env and CD4. Semin. Immunol. 10, 249±257.
(Wu et al., 1996; Farzan et al., 1997b) and the indicated concentration Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C.,
of unlabeled competitor. In experiments using gp120, 100 nM unla- and Lusso, P. (1995). Identification of RANTES, MIP-1 alpha, and
beled soluble CD4 was also included. Cells were washed twice in MIP-1 beta as the major HIV-suppressive factors produced by CD81
binding buffer containing 500 mM NaCl, and bound 125I was counted T cells. Science 270, 1811±1815.
in a gamma counter. Aliquots of the same cells used for binding
Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., and Landau,experiments were also analyzed for CCR5 expression by FACS.
N.R. (1997). Change in coreceptor use correlates with disease pro-
gression in HIV-1-infected individuals. J. Exp. Med. 185, 621±628.
Assaying the Ability of CCR5 Variants to Support
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M.,
HIV-1 Infection
Di Marzio, P., Marmon, S., Sutton, R.E., Hill, C.M., et al. (1996).
HIV entry into Cf2Th cells expressing CD4 and wild-type or mutant
Identification of a major co-receptor for primary isolates of HIV-1.
CCR5 proteins was measured as previously described (Choe et al.,
Nature 381, 661±666.
1996). Briefly, HIV-1 proviral DNA lacking a functional envelope gene
Deng, H.K., Unutmaz, D., KewalRamani, V.N., and Littman, D.R.and encoding chloramphenicol acetyltransferase (CAT) as a reporter
(1997). Expression cloning of new receptors used by simian andwas cotransfected into HeLa cells with plasmids encoding the enve-
human immunodeficiency viruses. Nature 388, 296±300.lope glycoproteins of the ADA, YU2, or 89.6 primary HIV-1 isolates.
Doms, R.W., and Peiper, S.C. (1997). Unwelcomed guests with mas-Viruses harvested from cell supernatants corresponding to 2,000 to
ter keys: how HIV uses chemokine receptors for cellular entry. Virol-10,000 cpm reverse transcriptase activity were incubated for 1 hr
ogy 235, 179±190.at 378C with Cf2Th cells transfected with CD4 and with varying (1±15
mg) amounts of the coreceptor-expressing plasmid. In all transfec- Doranz, B.J., Rucker, J., Yi, Y., Smyth, R.J., Samson, M., Peiper,
tions, the total amount of DNA was kept constant by including a S.C., Parmentier, M., Collman, R.G., and Doms, R.W. (1996). A dual-
plasmid encoding the pcDNA3.1 vector alone. Sixty hours postinfec- tropic primary HIV-1 isolate that uses fusin and the beta-chemokine
tion cells were lysed and CAT activity was measured. In parallel receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85,
with the infection experiments, coreceptor expression was quanti- 1149±1158.
tated by FACS analysis with the antibody 2D7. Entry values for Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Naga-
variant CCR5 receptors are expressed as a percentage of wild-type shima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P.,
CCR5 entry at the same cell surface expression level, calculated and Paxton, W.A. (1996). HIV-1 entry into CD41 cells is mediated
from a standard curve of entry versus cell surface expression of by the chemokine receptor CC- CKR-5. Nature 381, 667±673.
wild-type, codon-optimized CCR5.
Dragic, T., Trkola, A., Lin, S.W., Nagashima, K.A., Kajumo, F., Zhao,
L., Olson, W.C., Wu, L., Mackay, C.R., Allaway, G.P., et al. (1998).
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